Abstract Number: 2190 • 2015 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Core Laboratory Validation Exercise: Comparison of Enzyme-Linked Immunosorbant Assay (ELISA) and Chemiluminescence Immunoassay (CIA)
Background/Purpose: APS ACTION International Clinical Database and Repository was created to study the natural course of disease over 10 years in persistently aPL-positive patients with/without…Abstract Number: 2191 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Acute and Chronic Renal Lesions Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Background/Purpose : Renal lesions have been described in patients with antiphospholipid antibodies (aPL), however their associations with aPL are inconsistent among studies. Therefore our objective…Abstract Number: 2192 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Thrombocytopenia Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Background/Purpose : Thrombocytopenia is present in patients with systemic lupus erythematosus (SLE), and the role of antiphospholipid antibodies (aPL) is controversial. Therefore our objective was…Abstract Number: 2193 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Hemolytic Anemia Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Title: Increased Risk of Hemolytic Anemia Associated With Antiphospholipid Antibodies in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.Background/Purpose : Hemolytic anemia (HA)…Abstract Number: 2194 • 2015 ACR/ARHP Annual Meeting
Anticoagulation and Longterm Outcomes in Patients with Renal Artery Stenosis and Antiphospholipid Syndrome
Background/Purpose: Our previous data showed renal artery stenosis (RAS) is more prevalent in antiphospholipid syndrome(APS)(26%) compared to the general hypertensive population(8%),and anticoagulation with INR>=3 was…Abstract Number: 2195 • 2015 ACR/ARHP Annual Meeting
Long Term Outcome of Primary Antiphospholipid Syndrome Patients: A Multicenter Study
Background/Purpose: Data on the long-term outcome in primary antiphospholipid syndrome (PAPS) patients (pt) are still very limited.The objectives of this work was to assess the…Abstract Number: 2196 • 2015 ACR/ARHP Annual Meeting
Association Between Antiphospholipid Antibodies and All-Cause Mortality Among End Stage Renal Disease Patients with and without SLE
Background/Purpose: We investigated the association between the presence of antiphospholipid antibodies (aPL) and/or lupus anticoagulant (LAC) (aPL/LAC+) and all-cause mortality among end stage renal…Abstract Number: 2197 • 2015 ACR/ARHP Annual Meeting
Risk Factors for Adverse Pregnancy Outcome in First-Line Treated Pregnancies in Antiphospholip Antibodies-Positive Women According to Different Treatment Protocols: A Single Center Experience over 30 Years
Background/Purpose: Antiphospholipid antibodies (aPL) are risk factors for Adverse Pregnancy Outcome (APO). Risk stratification may include several demographic, clinical and serological variables. Still debated is…Abstract Number: 2198 • 2015 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Clinical Database and Repository Analysis: Determinants of Thrombosis in Patients Presenting with Obstetric APS
Background/Purpose: APS ACTION Clinical Database and Repository (“Registry”) was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive…Abstract Number: 2199 • 2015 ACR/ARHP Annual Meeting
in Vivo Ubiquinol Supplementation Reduces the Pro-Atherothrombotic Status in Antiphospholipid Syndrome Patients. Preliminary Results of a Clinical Trial
Background/Purpose: To investigate the beneficial effects of in vivoubiquinol (Q, reduced form of CoQ10) supplementation on athero-thrombosis prevention in APS patients, through the implementation of…Abstract Number: 2200 • 2015 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository Cluster Analysis: Identification of Different Clinical Phenotypes Among Antiphospholipid Antibody-Positive Female Patients
Background/Purpose: APS ACTION International Clinical Database and Repository was created to study the natural course of persistently antiphospholipid antibodies (aPL)-positive patients ± autoimmune disorders over…Abstract Number: 2201 • 2015 ACR/ARHP Annual Meeting
Triple Positivity of Antiphospholipid Antibody As the Main Thrombotic Factor in a Long-Term Follow-up Study of 98 Asymptomatic Apl-Positive Carriers
Background/Purpose: There is limited data regarding the long-term risk of developing a first-time thrombotic event and prophylactic benefits of aspirin use in asymptomatic aPL-positive carriers.…Abstract Number: 2202 • 2015 ACR/ARHP Annual Meeting
Different Patterns of Positivity for IgG Anti-Cardiolipin, Anti-Beta-2-Glycoprotein I and Anti-Domain I Antibodies within the First Year of Disease in 501 Patients with SLE – Associations with Different Clinical Outcomes
Background/Purpose: Antiphospholipid Syndrome (APS) is an autoimmune rheumatic disorder in which antiphospholipid antibodies (aPL) cause clinical sequelae including vascular events (VE) and pregnancy morbidity (PM).…Abstract Number: 2203 • 2015 ACR/ARHP Annual Meeting
Loss of Wdfy3 Leads to Enhanced Osteoclastogenesis Via NF-κB Activation
Background/Purpose: Autophagy and phagocytosis are conserved cellular functions involved in the protein degradation process in immunity. Recently, autophagy-related proteins were shown to regulate osteoclast mediated…Abstract Number: 2204 • 2015 ACR/ARHP Annual Meeting
Tankyrase Regulates Osteoclastogenesis Via SH3BP2 Expression
Background/Purpose: SH3BP2, an adaptor protein, is dominantly expressed in immune cells including macrophages and regulates intracellular signaling pathways. Gain-of-function mutations in SH3BP2 cause human genetic…
ACR Meeting Abstracts